Compare TYRA & SENEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | SENEA |
|---|---|---|
| Founded | 2018 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2021 | 1998 |
| Metric | TYRA | SENEA |
|---|---|---|
| Price | $20.07 | $177.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $47.45 | N/A |
| AVG Volume (30 Days) | ★ 957.1K | 69.7K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.85 |
| Revenue | N/A | ★ $1,314,765,000.00 |
| Revenue This Year | N/A | $14.06 |
| Revenue Next Year | N/A | $2.32 |
| P/E Ratio | ★ N/A | $62.12 |
| Revenue Growth | N/A | ★ 4.16 |
| 52 Week Low | $13.35 | $99.58 |
| 52 Week High | $40.65 | $210.00 |
| Indicator | TYRA | SENEA |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 47.71 |
| Support Level | $18.66 | $177.16 |
| Resistance Level | $27.00 | $181.43 |
| Average True Range (ATR) | 1.12 | 5.32 |
| MACD | -0.14 | -0.41 |
| Stochastic Oscillator | 7.94 | 56.58 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Seneca Foods Corp is a provider of packaged fruits and vegetables. The facilities are comprised of plants for packaging, can manufacturing, seed production, a farming operation and a logistical support network. It manages its business almost entirely on the basis of two reportable food packaging segments: Vegetable and Fruit/Snack. Majority of revenue comes from Vegetable segment. The Other category comprises non-food operations including revenue derived from the sale of cans, ends, seed, and outside revenue from the company's aircraft operations, and certain corporate items. Its principal product offerings include canned, frozen and jarred fruits and vegetables, as well as packaged snack chips. Its brands are Aunt Nellie's, Cherry man, GREEN VALLEY, Libby's, READ, and SENECA APPLE CHIPS.